Search Follow us

Simavita (SVA)

Business description

Simavita listed on TSX-V in Dec 2013 and ASX in Feb 2014. Its SIM platform technology is an integrated assessment device that helps manage urinary incontinence. The devices are used in residential and nursing home settings to optimise incontinence care.

First European distributor appointed

Update | Pharmaceutical & healthcare | 03/02/2015

Simavita’s SIM (Smart Incontinence Management) platform has been well received among key early adopters, for its ability to improve management of urinary incontinence in residential care settings. Simavita has appointed its first European distributor, Abena A/S in Denmark, after a successful trial in Copenhagen. We expect sales to accelerate as aged care providers complete assessment of trial sites, but additional funding may be required near term. Our DCF model suggests a valuation of A$100m.

Edison's research is freely available. We will never ask for your credit card details and you do not need to register. By downloading this research you are agreeing to our terms and conditions, which you can read in full here.

Stock data

Market cap.A$2.6m
Last closeA$0.022
High / Low (52 weeks)A$0.1 / A$0.0
Stock market listingAU
Forecast net cash (A$m)10.1
Forecast gearing ratio (%)N/A
TeamHealthcare
SectorPharmaceutical & healthcare

Price performance

%1m3m12m
Actual(4.3)(26.7)(56.2)
Relative *(5.4)(27.6)(58.3)

* % Relative to local index

Company news